104 related articles for article (PubMed ID: 19579436)
1. [New therapeutic possibilities in chronic ITP in adults].
Jönsson S; Olsson B; Wadenvik H
Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1476-9. PubMed ID: 19579436
[No Abstract] [Full Text] [Related]
2. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
Godeau B;
Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
[No Abstract] [Full Text] [Related]
3. Two new drugs for chronic ITP.
Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
[TBL] [Abstract][Full Text] [Related]
4. [Management of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia, ITP)].
Kashiwagi H; Tomiyama Y
Rinsho Ketsueki; 2014 Oct; 55(10):2087-94. PubMed ID: 25297775
[No Abstract] [Full Text] [Related]
5. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura.
D'Arena G; Guariglia R; Mansueto G; Martorelli MC; Pietrantuono G; Villani O; Lerose R; Musto P
Blood; 2013 Feb; 121(7):1240-2. PubMed ID: 23411736
[No Abstract] [Full Text] [Related]
6. Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.
Scaramucci L; Giovannini M; Niscola P; Tendas A; Perrotti A; De Fabritiis P
Blood Transfus; 2014 Oct; 12(4):605-7. PubMed ID: 25351191
[No Abstract] [Full Text] [Related]
7. Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
Ferretti A; Baldacci E; Miulli E; Canichella M; Di Rocco A; Pulsoni A; Martelli M; Serrao A; Chistolini A; Gabriella Mazzucconi M; Foà R; Santoro C
Br J Haematol; 2019 Sep; 186(6):e217-e219. PubMed ID: 31364154
[No Abstract] [Full Text] [Related]
8. Sustaining platelet counts in chronic ITP.
Nurden AT
Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056
[No Abstract] [Full Text] [Related]
9. Orphan disease gains second treatment option.
Morrow T
Manag Care; 2009 Jan; 18(1):47-9. PubMed ID: 19186672
[No Abstract] [Full Text] [Related]
10. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
[TBL] [Abstract][Full Text] [Related]
11. Initial Experience with the Use of Thrombopoetin Receptor Agonists in Patients with Refractory HIV-Associated Immune Thrombocytopenic Purpura: A Case Series.
Kowalczyk M; Rubinstein PG; Aboulafia DM
J Int Assoc Provid AIDS Care; 2015; 14(3):211-6. PubMed ID: 25504472
[TBL] [Abstract][Full Text] [Related]
12. New options after first-line therapy for chronic immune thrombocytopenic purpura.
Burzynski J
Am J Health Syst Pharm; 2009 Jan; 66(2 Suppl 2):S11-21. PubMed ID: 19139486
[TBL] [Abstract][Full Text] [Related]
13. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
Iino M; Sakamoto Y; Sato T
Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
[TBL] [Abstract][Full Text] [Related]
14. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents.
Ghanima W; Junker P; Hasselbalch HC; Boiocchi L; Geyer JT; Feng X; Gudbrandsdottir S; Orazi A; Bussel JB
Br J Haematol; 2011 Oct; 155(2):248-55. PubMed ID: 21902682
[TBL] [Abstract][Full Text] [Related]
15. "ITP" is not always immune thrombocytopenia.
Holyome A; Cooper N; Qureshi A; Bain BJ
Am J Hematol; 2020 Dec; 95(12):1614-1615. PubMed ID: 32419170
[No Abstract] [Full Text] [Related]
16. Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center.
Suntsova EV; Maschan AA; Baydildina DD; Kalinina II; Petrova UN; Pshonkin AV; Novichkova GA
Pediatr Blood Cancer; 2019 Jun; 66(6):e27704. PubMed ID: 30854783
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.
Fattizzo B; Pasquale R; Carpenedo M; Cantoni S; Auteri G; Gramegna D; D'Adda M; Napolitano M; Consonni D; Ruggeri M; Siragusa S; Rossi G; Vianelli N; Barcellini W
Haematologica; 2019 Oct; 104(10):e470-e473. PubMed ID: 30846501
[No Abstract] [Full Text] [Related]
18. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
[TBL] [Abstract][Full Text] [Related]
19. [Recent advances in the treatment of idiopathic thrombocytopenic purpura].
Kurata Y
Rinsho Ketsueki; 2007 May; 48(5):355-62. PubMed ID: 17571579
[No Abstract] [Full Text] [Related]
20. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study.
Michel M; Ruggeri M; Gonzalez-Lopez TJ; Alkindi S; Cheze S; Ghanima W; Tvedt THA; Ebbo M; Terriou L; Bussel JB; Godeau B
Blood; 2020 Dec; 136(26):3056-3061. PubMed ID: 32814348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
